| Literature DB >> 18471297 |
Juliet Nabyonga-Orem1, Humphrey Karamagi, Lynn Atuyambe, Fred Bagenda, Sam A Okuonzi, Oladapo Walker.
Abstract
BACKGROUND: It has been argued that quality improvements that result from user charges reduce their negative impact on utilization especially of the poor. In Uganda, because there was no concrete evidence for improvements in quality of care following the introduction of user charges, the government abolished user fees in all public health units on 1st March 2001. This gave us the opportunity to prospectively study how different aspects of quality of care change, as a country changes its health financing options from user charges to free services, in a developing country setting. The outcome of the study may then provide insights into policy actions to maintain quality of care following removal of user fees.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18471297 PMCID: PMC2397390 DOI: 10.1186/1472-6963-8-102
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Sampled numbers and type of health units by district and ownership.
| Type of HU | Mbde | Nebbi | Rakai | R'ri | Soroti | Mbde | Nebbi | Rakai | R'ri | Soroti | |||
| Hospital | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | |||
| HC IV | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |||
| HC III | 4 | 3 | 1 | 3 | 8 | 6 | 3 | 5 | 5 | 2 | |||
| HC II | 2 | 12 | 4 | 6 | 1 | 0 | 0 | 1 | 4 | 1 | |||
Figure 1Average annual drug receipts for Chloroquine and cotrimoxazole. CQ: Chloroquine CTRXZ: Cotrimoxazole.
Regression analysis to determine if there was any significant change in drug availability after the abolition of cost sharing:
| Dependent Variable [Log of Drug Availability] | ||
| Explanatory Variables | OLS Coefficient | Random Effects |
| Referral | -0.071 | -0.0675 |
| [-1.01] | [-0.51] | |
| Public | 1.092*** | 1.085*** |
| [14.55] | [7.81] | |
| Choroquine | -0.0257 | -0.031 |
| [-0.37] | [-.045] | |
| Dummy March 2001 | -0.074 | -0.074 |
| [-1.05] | [-1.07] | |
| Constant | 1.216 | 9.23 |
| Number of Observations | 2267 | 2267 |
| Number of groups | - | 32 |
| Adjusted R-Squared | 0.289 | - |
| F(4,2262) | 56.88 | - |
| Prob >F | 0 | - |
| Wald Chi2(4) | - | 66.8 |
| Prob>chi | - | 0 |
| Notes: t values in parenthesis | ||
Figure 2Average monthly stock out days for facilities assessed for the period 2000 – 2003. CQ: Chloroquine CTRXZ: Cotrimoxazole.
Figure 3Average monthly drug receipts/OPD case for the period 2000 – 2003. CQ: Chloroquine CTRXZ: Cotrimoxazole.
Figure 4Number of providers seen by communities in different categories of providers.
Figure 5Average time spent with each provider in the different catchment areas.